

IN THE CLAIMS:

1. (Currently Amended) A recombinant polynucleotide encoding a polypeptide comprising the amino acid sequence (SEQ ID NO: 1):

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QQWERTYLGN VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVVD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRRDN MKWC GTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDMDH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSIPP RN LGY
```

or variants or fragments or derivatives or fusions thereof or fusions of said variants or fragments or derivatives.

2. (Currently Amended) A polynucleotide according to Claim 1, encoding a polypeptide comprising the amino acid sequence shown in Figure 2 [labelled] labeled pMSF1 $\alpha$  between positions 19 and 660 (SEQ ID NO: 36), or variants or fragments or derivatives or fusions thereof or fusions of said variants or fragments or derivatives.
3. (Previously Amended) A polynucleotide according to Claim 1, which contains no introns.
4. (Currently Amended) A polynucleotide according to Claim 1, comprising the polynucleotide whose sequence is shown in Figure 1 (SEQ ID NO: 2).
5. (Currently Amended) A polynucleotide according to Claim 1, comprising the polynucleotide whose sequence is shown in Figure 1 between positions 57 and 1982 (SEQ ID NO: 41).
6. (Previously Amended) A polynucleotide according to Claim 1, encoding a polypeptide which has migration stimulation factor activity.

7. (Previously Amended) A replicable vector comprising a polynucleotide as defined in Claim 1.
8. (Previously Amended) A host cell comprising a recombinant polynucleotide as defined in Claim 1 or a replicable vector comprising the polynucleotide.
9. (Currently Amended) A method of making a polypeptide having the amino acid sequence (SEQ ID NO: 1):

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVMD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCICTG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRDNR MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDGMH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSIPP RNLGY
```

or variants or fragments or fusions or derivatives thereof, or fusions of said variants or fragments or derivatives, the method comprising culturing a host cell as defined in Claim 8 which expresses said variant or fragment or derivative or fusion and isolating said polypeptide or variant or fragment or derivative or fusion from said host cell culture.

10. (Currently Amended) A polypeptide comprising the amino acids sequence (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVMD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCICTG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRDNR MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDGMH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSIPP RNLGY
```

or variants or fragments or fusions or derivatives thereof or fusions of said variants or fragments or derivatives.

11. (Currently Amended) A polypeptide according to Claim 10, comprising the amino acid sequence shown in Figure 2 [labelled] labeled pMSF1 $\alpha$  between positions 19 and 660 (SEQ ID NO: 36), or variants or fragments or fusions

thereof or fusions of said variants or fragments.

12. (Original) A polypeptide obtainable by the method of Claim 9.
13. (Previously Amended) A polypeptide according to Claim 10, which has migration stimulating factor activity.
14. (Currently Amended) An antibody reactive towards the polypeptide whose amino acid sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVVD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHPQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRD N MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHD MGH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSI PP RNLGY
```

or natural variants thereof but not reactive towards fibronectin (SEQ ID NO: 46).

15. (Currently Amended) An antibody reactive towards the polypeptide whose amino acid sequence is shown in Figure 2 [labelled] labeled pMSF1 $\alpha$  between positions 19 and 660 (SEQ ID NO: 36) or natural variants thereof but not reactive towards fibronectin (SEQ ID NO: 46).
16. (Currently Amended) An antibody reactive towards an epitope present in the polypeptide whose amino acid sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVVD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHPQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRD N MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHD MGH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSI PP RNLGY
```

or natural variants thereof but which epitope is not present in fibronectin (SEQ ID NO: 46).

17. (Currently Amended) An antibody reactive towards an epitope present in the polypeptide whose amino acid sequence is shown in Figure 2 [labelled] labeled

pMSF1 $\alpha$  between positions 19 to 660 (SEQ ID NO: 36) or natural variants thereof but which epitope is not present in fibronectin (SEQ ID NO: 46).

18. (Currently Amended) An antibody according to any one of Claims 14 to 17, reactive towards a molecule comprising any one of the peptides  
ISKYILRWRPVSIIPRNLGY (SEQ ID NO: 3) or  
QQWERTYLGNALVCTCYGGS (SEQ ID NO: 4) or  
EPCVLPFTYNDRTDSTTSNYEQDQ (SEQ ID NO: 34) or  
CTDHTVLVQTRGGNSNGALCH (SEQ ID NO: 6)  
VGNGRGEWTCIAYSQLRDQCI (SEQ ID NO: 7).
19. (Currently Amended) An antibody reactive towards fibronectin (SEQ ID NO: 46) but not reactive towards the polypeptide whose amino acid sequence is (SEQ ID NO: 1)

NLVATCLPVR	ASLPHRLNML	RGP GPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLG	VLVCTCYGGS	RGFNCEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMVVD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICTG	NGRGEWK CER	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT
DHTVLVQTQG	GNSNGALCHF	PFLYNNHNYT	DCTSEGRRDN	MKWC GTTQNY	DADQKFGFCP
MAAHEEICTT	NEGVMYRIGD	QWDKQHDMGH	MMRCTCVGNG	RGEWTCYAYS	QLRDQCI VDD
ITYNVNDTFH	KRHEEGHMLN	CTCFGQGRGR	WKCDPVDQCQ	DSETGT FYQI	GDSWEKYVHG
VRYQCYCYGR	GIGEWHCQPL	QTYPSSSGPV	EVFITETPSQ	PNSHP IQWNA	PQPSHISKYI
LRWRPVSIIP	RNLGY				

or natural variants thereof.

20. (Currently Amended) An antibody reactive towards fibronectin (SEQ ID NO: 46) but not reactive towards the polypeptide whose amino acid sequence is shown in Figure 2 [labelled] labeled pMSF1 $\alpha$  between positions 19 and 660 (SEQ ID NO: 36) or natural variants thereof.
21. (Currently Amended) An antibody reactive towards an epitope present in fibronectin (SEQ ID NO: 46) but not present in the polypeptide whose amino acid sequence is (SEQ ID NO: 1)

NLVATCLPVR	ASLPHRLNML	RGP GPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLG	VLVCTCYGGS	RGFNCEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMVVD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICTG	NGRGEWK CER	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT

26. (Currently Amended) A method of making an antibody which is reactive towards fibronectin (SEQ ID NO: 46) and which is not reactive towards the polypeptide whose amino acid sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QQWERTYLGN VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMMD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRDN MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDMDH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTIFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSI PP RN LGY
```

or a natural variant thereof, the method comprising the steps of, where appropriate, [immunizing] immunizing an animal with a peptide which distinguishes fibronectin from MSF and selecting an antibody which binds fibronectin but does not substantially bind MSF.

27. (Currently Amended) A molecule which is capable of, following [immunisation] immunization of an animal if appropriate, giving rise to antibodies which are reactive towards the polypeptide whose sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QQWERTYLGN VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMMD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRDN MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDMDH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTIFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSI PP RN LGY
```

or natural variants thereof and but not reactive towards fibronectin (SEQ ID NO: 46).

28. (Currently Amended) A molecule which is capable of, following [immunisation] immunization of an animal if appropriate, giving rise to antibodies which are reactive towards fibronectin (SEQ ID NO: 46) but not reactive towards the polypeptide whose sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QQWERTYLGN VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMMD CTCLGEGSGR
```

```
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHPQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRRDN MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDMGH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSIPP RNLGY
```

or natural variants thereof.

29. (Currently Amended) A molecule according to Claim 27 which is a peptide comprising any one of the sequences ISKYILRWRPVSIPPRNLGY (SEQ ID NO: 3) or QQWERTYLGNALVCTCYGGSR (SEQ ID NO: 4) or PCVLPFTYNDRTDSTTSNYEQDQ (SEQ ID NO: 5) or TDHTVLVQTRGGNSNGALCH (SEQ ID NO: 35) or VGNGRGEWTCIAYSQLRDQCI (SEQ ID NO: 7) which are found in MSF.
30. (Currently Amended) A molecule according to Claim 28, which is a peptide comprising any one of the sequences QQWERTYLGNVLVCTCYGGSR (SEQ ID NO: 8) or EPCVLPFTYNGRTFYSCCTTEGRQDGHLWCSTTSNYEQDQ (SEQ ID NO: 9) or CTDHTVLVQTQGGNSNGALCH (SEQ ID NO: 10) or VGNGRGEWTCYAYSQLRDQCI (SEQ ID NO: 42) or ISKYILRWRP KNSVGRWKEA (SEQ ID NO: 43) or peptides derived from position 648 onwards in fibronectin (SEQ ID NO: 46) as shown in Figure 2.
31. (Currently Amended) A polynucleotide which is capable of distinguishing a polynucleotide which encodes the polypeptide whose sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGEQGLLLL AVLCLGTAVP STGASKSKRQ AQQMVPQSP
VAVSQSKPGC YDNGKHYQIN QQWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN GKGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHPQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRRDN MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHDMGH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSIPP RNLGY
```

or a natural variant thereof [and] from a polynucleotide which encodes fibronectin (SEQ ID NO: 46).

32. (Currently Amended) A polynucleotide which is capable of [hybridizing]  
hybridizing to a polynucleotide which encodes fibronectin (SEQ ID NO: 46) but  
not a polynucleotide which encodes the polypeptide whose sequence is (SEQ ID  
NO: 1)

NLVATCLPVR	ASLPHRLNML	RGPGPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLGN	VLVCTCYGGS	RGFNCESEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCKPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMMD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICIG	NGRGEWKCE	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT
DHTVLVQTQG	GNSNGALCHF	PFLYNNHNYT	DCTSEGRRDN	MKWCSTTQNY	DADQKFGFCP
MAAHEEICTT	NEGVMYRIGD	QWDKQHDMD	MMRCTCVGNG	RGEWTCYAYS	QLRDQCIQDD
ITYNVNDTFH	KRHEEGHMLN	CTCFGQGRGR	WKCDPVDQCQ	DSETGTFTYQI	GDSWEKYVHG
VRYQCYCYGR	GIGEWHCQPL	QTYPSSSGPV	EVFITETPSQ	PNSHPIQWNA	PQPSHISKYI
LRWRPVSIPP	RNLGY				

or a natural variant thereof.

33. (Currently Amended) A polynucleotide which is capable of [hybridizing]  
hybridizing to a polynucleotide which encodes the polypeptide whose sequence  
is (SEQ ID NO: 1)

NLVATCLPVR	ASLPHRLNML	RGPGPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLGN	VLVCTCYGGS	RGFNCESEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCKPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMMD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICIG	NGRGEWKCE	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT
DHTVLVQTQG	GNSNGALCHF	PFLYNNHNYT	DCTSEGRRDN	MKWCSTTQNY	DADQKFGFCP
MAAHEEICTT	NEGVMYRIGD	QWDKQHDMD	MMRCTCVGNG	RGEWTCYAYS	QLRDQCIQDD
ITYNVNDTFH	KRHEEGHMLN	CTCFGQGRGR	WKCDPVDQCQ	DSETGTFTYQI	GDSWEKYVHG
VRYQCYCYGR	GIGEWHCQPL	QTYPSSSGPV	EVFITETPSQ	PNSHPIQWNA	PQPSHISKYI
LRWRPVSIPP	RNLGY				

or a natural variant thereof but not to a polynucleotide which encodes fibronectin  
(SEQ ID NO: 46).

34. (Original) A polynucleotide according to any one of Claims 31 to 33, wherein  
the polynucleotide is an oligonucleotide.
35. (Previously Amended) A polynucleotide according to any one of Claims 31 to  
33, wherein the polynucleotide which encodes fibronectin or the polynucleotide  
which encodes the polypeptide as said or a natural variant thereof is a mRNA or  
cDNA.
36. (Currently Amended) A method of diagnosing cancer the method comprising

detecting in a sample from the person to be diagnosed the presence of a polypeptide whose sequence is (SEQ ID NO: 1)

NLVATCLPVR	ASLPHRLNML	RGPGPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLGN	VLVCTCYGGS	RGFNCEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCKPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMVMD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICIG	NGRGEWKCE	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT
DHTVLVQTQG	GNSNGALCHF	PFLYNNHNYT	DCTSEGRDNR	MKWCSTTQNY	DADQKFGFCP
MAAHEEICTT	NEGVMYRIGD	QWDKQHDMDH	MMRCTCVGNG	RGEWTCYAYS	QLRDQCIQVDD
ITYNVNDTFH	KRHEEGHMLN	CTCFGQGRGR	WKCDPVDQCC	DSETGTFTYQI	GDSWEKYVHG
VRYQCYCYGR	GIGEWHCQPL	QTYPSSSGPV	EVFITETPSQ	PNSHPIQWNA	PQPSHISKYI
LRWRPVSIPP	RNLGY				

or a natural variant or fragment thereof using a reagent which can distinguish said polypeptide from fibronectin (SEQ ID NO: 46).

37. (Currently Amended) A method of determining susceptibility to cancer the method comprising detecting in a sample derived from the person to be tested the presence of a polypeptide whose sequence is (SEQ ID NO: 1)

NLVATCLPVR	ASLPHRLNML	RGPGPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLGN	VLVCTCYGGS	RGFNCEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCKPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMVMD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICIG	NGRGEWKCE	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT
DHTVLVQTQG	GNSNGALCHF	PFLYNNHNYT	DCTSEGRDNR	MKWCSTTQNY	DADQKFGFCP
MAAHEEICTT	NEGVMYRIGD	QWDKQHDMDH	MMRCTCVGNG	RGEWTCYAYS	QLRDQCIQVDD
ITYNVNDTFH	KRHEEGHMLN	CTCFGQGRGR	WKCDPVDQCC	DSETGTFTYQI	GDSWEKYVHG
VRYQCYCYGR	GIGEWHCQPL	QTYPSSSGPV	EVFITETPSQ	PNSHPIQWNA	PQPSHISKYI
LRWRPVSIPP	RNLGY				

or a natural variant or fragment thereof using a reagent which can distinguish said polypeptide from fibronectin (SEQ ID NO: 46).

38. (Currently Amended) A method of determining the likely outcome of a patient with cancer the method comprising detecting in a sample from the patient the presence of a polypeptide whose sequence is (SEQ ID NO: 1)

NLVATCLPVR	ASLPHRLNML	RGPGPGLLLL	AVLCLGTAVP	STGASKSKRQ	AQQMVQPQSP
VAVSQSKPGC	YDNGKHYQIN	QQWERTYLGN	VLVCTCYGGS	RGFNCEKPE	AEETCFDKYT
GNTYRVGDTY	ERPKDSMIWD	CTCIGAGRGR	ISCTIANRCH	EGGQSYKIGD	TWRRPHETGG
YMLECVCLGN	GKGEWTCKPI	AEKCFDHAAG	TSYVVGETWE	KPYQGWMVMD	CTCLGEGSGR
ITCTSRNRCN	DQDTRTSYRI	GDTWSKKDNR	GNLLQCICIG	NGRGEWKCE	HTSVQTTSSG
SGPFTDVRAA	VYQPQPHQP	PPYGHCVTDS	GVVYSVGMQW	LKTQGNKQML	CTCLGNGVSC
QETAVTQTYG	GNSNGEPCVL	PFTYNGRTFY	SCTTEGRQDG	HLWCSTTSNY	EQDQKYSFCT
DHTVLVQTQG	GNSNGALCHF	PFLYNNHNYT	DCTSEGRDNR	MKWCSTTQNY	DADQKFGFCP
MAAHEEICTT	NEGVMYRIGD	QWDKQHDMDH	MMRCTCVGNG	RGEWTCYAYS	QLRDQCIQVDD



ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG  
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI  
LRWRPVSIPP RNLGY

or a natural variant or fragment thereof using a reagent which can distinguish said polypeptide from fibronectin (SEQ ID NO: 46).

39. (Previously Amended) A method according to any one of Claims 36 to 38, wherein the reagent which can distinguish said polypeptide from fibronectin is an antibody according to any one of Claims 14 to 17.
40. (Currently Amended) A method of diagnosing cancer the method comprising detecting in a sample from the person to be diagnosed a polynucleotide encoding a polypeptide whose sequence is (SEQ ID NO: 1)

NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVPQSP  
VAVSQSKPGC YDNGKHYQIN QWERTYLGN VLVCTCYGGS RGFNCESKPE AEETCFDKYT  
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG  
YMLECVCLGN KGGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVMD CTCLGEGSGR  
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCICTG NGRGEWK CER HTSVQTTSSG  
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLNGVSC  
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT  
DHTVLVQTQG GNSNGALCHF PELYNHNHNYT DCTSEGRRDN MKWCGTTQNY DADQKFGFCP  
MAAHEEICTT NEGVMYRIGD QWDKQHDMDH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD  
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG  
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI  
LRWRPVSIPP RNLGY

or a natural variant thereof using a reagent which can distinguish said polynucleotide from a polynucleotide encoding fibronectin (SEQ ID NO: 46).

41. (Currently Amended) A method of determining susceptibility to cancer the method comprising detecting in a sample derived from the person to be tested the presence of a polynucleotide encoding a polypeptide whose sequence is (SEQ ID NO: 1)

NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVPQSP  
VAVSQSKPGC YDNGKHYQIN QWERTYLGN VLVCTCYGGS RGFNCESKPE AEETCFDKYT  
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG  
YMLECVCLGN KGGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVMD CTCLGEGSGR  
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCICTG NGRGEWK CER HTSVQTTSSG  
SGPFTDVRAA VYQPQPHQP PPYGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLNGVSC  
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT  
DHTVLVQTQG GNSNGALCHF PELYNHNHNYT DCTSEGRRDN MKWCGTTQNY DADQKFGFCP  
MAAHEEICTT NEGVMYRIGD QWDKQHDMDH MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD  
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG  
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI  
LRWRPVSIPP RNLGY

or a natural variant thereof using a reagent which can distinguish said polynucleotide

from a polynucleotide encoding fibronectin (SEQ ID NO: 46).

42. (Currently Amended) A method of determining the likely outcome of a patient with cancer the method comprising detecting in a sample from the patient the presence of a polynucleotide encoding a polypeptide whose sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN KGGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVMD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRRDN MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHD MG H MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSI PP RNLGY
```

or a natural variant or fragment thereof using a reagent which said polynucleotide from a polynucleotide encoding fibronectin (SEQ ID NO: 46).

43. (Original) A method according to any one of Claims 40 to 42, wherein the reagent which can distinguish said polynucleotide from a polynucleotide encoding fibronectin (SEQ ID NO: 46) is a polynucleotide according to Claim 31 or 33.
44. (Previously Amended) A method according to any one of Claims 36 to 38 and 40 to 42, wherein the cancer is breast cancer.
45. (Currently Amended) Use of a reagent which can distinguish the polypeptide whose sequence is (SEQ ID NO: 1)

```
NLVATCLPVR ASLPHRLNML RGP GPGLLLL AVLCLGTAVP STGASKSKRQ AQQMVQPQSP
VAVSQSKPGC YDNGKHYQIN QWERTYLG N VLVCTCYGGS RGFNCESKPE AEETCFDKYT
GNTYRVGDTY ERPKDSMIWD CTCIGAGRGR ISCTIANRCH EGGQSYKIGD TWRRPHETGG
YMLECVCLGN KGGEWTCKPI AEKCFDHAAG TSYVVGETWE KPYQGWMVMD CTCLGEGSGR
ITCTSRNRCN DQDTRTSYRI GDTWSKKDNR GNLLQCIC TG NGRGEWK CER HTSVQTTSSG
SGPFTDVRAA VYQPQPHQP PPGHCVTDS GVVYSVGMQW LKTQGNKQML CTCLGNGVSC
QETAVTQTYG GNSNGEPCVL PFTYNGRTFY SCTTEGRQDG HLWCSTTSNY EQDQKYSFCT
DHTVLVQTQG GNSNGALCHF PFLYNNHNYT DCTSEGRRDN MKWCGTTQNY DADQKFGFCP
MAAHEEICTT NEGVMYRIGD QWDKQHD MG H MMRCTCVGNG RGEWTCYAYS QLRDQCIVDD
ITYNVNDTFH KRHEEGHMLN CTCFGQGRGR WKCDPVDQCQ DSETGTFYQI GDSWEKYVHG
VRYQCYCYGR GIGEWHCQPL QTYPSSSGPV EVFITETPSQ PNSHPIQWNA PQPSHISKYI
LRWRPVSI PP RNLGY
```

or a natural variant thereof from fibronectin (SEQ ID NO: 46) in the manufacture of a reagent for diagnosing cancer.

46. (Original) Use of a reagent as defined in Claim 45, as a diagnostic agent.
47. (Previously Amended) A method of modulating cell migration the method comprising administering an effective amount of a polypeptide according to any one of Claims 10 and 12 to the site where modulation of cell migration is required.
48. (Original) A method according to Claim 47, wherein the cell is a fibroblast or an endothelial cell.
49. (Previously Amended) A method according to Claim 47, wherein the site is in a mammalian body.
50. (Original) A method according to Claim 49 wherein the site is in a human body.
51. (Previously Amended) Use of a polypeptide according to any one of Claims 10 and 12, in the manufacture of an agent for modulating cell migration.
52. (Previously Amended) Use of a polypeptide according to any one of Claims 10 and 12, for modulating cell migration.
53. (Previously Amended) A method of healing a wound the method comprising administering to the locality of the wound an effective amount of a polypeptide according to any one of Claims 10 and 12.
54. (Previously Amended) Use of a polypeptide according to any one of Claims 10 and 12, in manufacture of a medicament for healing wounds.
55. (Previously Amended) Use of a polypeptide according to any one of Claims 10 and 12, for healing wounds.
56. (Previously Amended) A pharmaceutical composition comprising a polypeptide according to any one of Claims 10 and 12 and a pharmaceutically acceptable carrier.
57. (Previously Amended) A polypeptide according to any one of Claims 10 and 12 for use in medicine.
58. (Previously Amended) A method of preventing scarring comprising administering to the locality of the site where scarring is to be prevented an effective amount of a polypeptide according to any one of Claims 10 and 12.
59. (Previously Added) A polypeptide according to Claim 12, which has migration stimulating factor activity.